JP2010535025A - 肺炎球菌抗原を含む組成物 - Google Patents

肺炎球菌抗原を含む組成物 Download PDF

Info

Publication number
JP2010535025A
JP2010535025A JP2010518777A JP2010518777A JP2010535025A JP 2010535025 A JP2010535025 A JP 2010535025A JP 2010518777 A JP2010518777 A JP 2010518777A JP 2010518777 A JP2010518777 A JP 2010518777A JP 2010535025 A JP2010535025 A JP 2010535025A
Authority
JP
Japan
Prior art keywords
seq
antigen
amino acids
preferred
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010518777A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010535025A5 (enExample
Inventor
クラウディオ ドナーティ,
アレッサンドロ ムッズィ,
ヴェガ マシグナニ,
ファビオ バニョリ,
パオロ ルッジェーロ,
ミッチェル バロッチ,
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2010535025A publication Critical patent/JP2010535025A/ja
Publication of JP2010535025A5 publication Critical patent/JP2010535025A5/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/09Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092Streptococcus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/40Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2010518777A 2007-08-01 2008-08-01 肺炎球菌抗原を含む組成物 Pending JP2010535025A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0714963.6A GB0714963D0 (en) 2007-08-01 2007-08-01 Compositions comprising antigens
US96686607P 2007-08-29 2007-08-29
PCT/IB2008/002866 WO2009016515A2 (en) 2007-08-01 2008-08-01 Compositions comprising pneumococcal antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013230378A Division JP5838193B2 (ja) 2007-08-01 2013-11-06 肺炎球菌抗原を含む組成物

Publications (2)

Publication Number Publication Date
JP2010535025A true JP2010535025A (ja) 2010-11-18
JP2010535025A5 JP2010535025A5 (enExample) 2012-09-13

Family

ID=38529101

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010518777A Pending JP2010535025A (ja) 2007-08-01 2008-08-01 肺炎球菌抗原を含む組成物
JP2013230378A Expired - Fee Related JP5838193B2 (ja) 2007-08-01 2013-11-06 肺炎球菌抗原を含む組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013230378A Expired - Fee Related JP5838193B2 (ja) 2007-08-01 2013-11-06 肺炎球菌抗原を含む組成物

Country Status (20)

Country Link
US (2) US20110243976A1 (enExample)
EP (2) EP2197484A2 (enExample)
JP (2) JP2010535025A (enExample)
CN (2) CN104001165B (enExample)
AP (1) AP2010005173A0 (enExample)
AU (1) AU2008281438A1 (enExample)
BR (1) BRPI0813892A2 (enExample)
CA (1) CA2695169A1 (enExample)
CO (1) CO6260103A2 (enExample)
CY (1) CY1117689T1 (enExample)
DK (1) DK2572726T3 (enExample)
EA (1) EA018137B1 (enExample)
ES (1) ES2580957T3 (enExample)
GB (1) GB0714963D0 (enExample)
HR (1) HRP20160685T1 (enExample)
HU (1) HUE029670T2 (enExample)
PL (1) PL2572726T3 (enExample)
PT (1) PT2572726T (enExample)
SI (1) SI2572726T1 (enExample)
WO (1) WO2009016515A2 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015501329A (ja) * 2011-11-07 2015-01-15 ノバルティス アーゲー spr0096抗原およびspr2021抗原を含むキャリア分子
JP2019065035A (ja) * 2011-04-29 2019-04-25 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. 抗体反応を低下させる寛容原性合成ナノキャリア
US11298342B2 (en) 2013-05-03 2022-04-12 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
US11633422B2 (en) 2014-09-07 2023-04-25 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
EP2265634A2 (en) * 2008-03-17 2010-12-29 Intercell AG Peptides protective against s. pneumoniae and compositions, methods and uses relating thereto
ATE523204T1 (de) * 2009-02-16 2011-09-15 Karlsruher Inst Technologie Cd44v6-peptide als bakterielle infektionsinhibitoren
ES2531115T3 (es) 2009-06-01 2015-03-10 Novartis Ag Combinaciones de clados de RrgB neumocócicos
WO2011008548A1 (en) 2009-06-29 2011-01-20 Genocea Biosciences, Inc. Vaccines and compositions against streptococcus pneumoniae
CA2773637A1 (en) * 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
US9649372B2 (en) 2009-12-22 2017-05-16 Sanofi Pasteur Limited Immunogenic compositions and related methods
EP2550289A4 (en) 2010-03-12 2013-11-27 Childrens Medical Center NEW IMMUNOGENES AND METHODS FOR IDENTIFICATION AND SCREENING THEREOF
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
DK2590676T3 (en) 2010-07-06 2016-10-24 Glaxosmithkline Biologicals Sa Virionlignende feed particles to self-replicating RNA molecules
JP5940064B2 (ja) 2010-07-06 2016-06-29 ノバルティス アーゲー 低用量のrnaを用いた大型哺乳動物の免疫化
RS54489B1 (sr) 2010-07-06 2016-06-30 Glaxosmithkline Biologicals Sa Lipozomi sa lipidima koji imaju poboljšanu pka vrednost za oslobađanje rnk
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
HUE047796T2 (hu) 2010-07-06 2020-05-28 Glaxosmithkline Biologicals Sa RNS bevitele több immunútvonal bekapcsolására
US9770463B2 (en) 2010-07-06 2017-09-26 Glaxosmithkline Biologicals Sa Delivery of RNA to different cell types
PL3831406T3 (pl) 2010-08-23 2024-09-09 Wyeth Llc Stabilne preparaty antygenów rLP2086 Neisseria meningitidis
BR112013004865A2 (pt) 2010-08-31 2016-06-07 Novartis Ag lípidos adequados para entrega lipossomal de codificadores de proteínas rna
SMT202200311T1 (it) 2010-08-31 2022-09-14 Glaxosmithkline Biologicals Sa Liposomi pegilati per somministrare rna codificante un immunogene
RU2546873C2 (ru) * 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
EP3520813B1 (en) 2010-10-11 2023-04-19 GlaxoSmithKline Biologicals S.A. Antigen delivery platforms
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
MX344120B (es) 2011-01-20 2016-12-06 Genocea Biosciences Inc Vacunas y composiciones contra streptococcus pneumoniae.
AU2012253359B2 (en) 2011-05-11 2017-06-08 Children's Medical Center Corporation Multiple antigen presenting immunogenic composition, and methods and uses thereof
EP3854413A1 (en) 2011-07-06 2021-07-28 GlaxoSmithKline Biologicals SA Immunogenic combination compositions and uses thereof
US20140141070A1 (en) 2011-07-06 2014-05-22 Andrew Geall Liposomes having useful n:p ratio for delivery of rna molecules
US20140255472A1 (en) 2011-08-31 2014-09-11 Andrew Geall Pegylated liposomes for delivery of immunogen-encoding rna
DK3369742T3 (da) * 2011-10-05 2020-10-19 Univ Rockefeller Dimere bakteriofaglysiner
EP2822586A1 (en) 2012-03-07 2015-01-14 Novartis AG Adjuvanted formulations of streptococcus pneumoniae antigens
MY167723A (en) 2012-03-09 2018-09-21 Pfizer Neisseria meningitidis compositions and methods thereof
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
EP4056198A3 (en) 2012-09-18 2022-12-07 GlaxoSmithKline Biologicals SA Outer membrane vesicles
KR20140075196A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2900008C (en) * 2013-02-07 2025-10-07 Children's Medical Center Corporation PROTEIN ANTIGENS THAT CONFER PROTECTION AGAINST COLONIZATION AND/OR PNEUMOCOCCAL DISEASE
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
KR102255108B1 (ko) 2013-03-08 2021-05-24 노파르티스 아게 활성제의 전달을 위한 지질 및 지질 조성물
EP4098276A1 (en) 2013-09-08 2022-12-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3623361B1 (en) 2013-12-19 2021-08-18 Novartis AG Lipids and lipid compositions for the delivery of active agents
ES2908827T3 (es) 2013-12-19 2022-05-04 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
WO2016010840A1 (en) 2014-07-16 2016-01-21 Novartis Ag Method of encapsulating a nucleic acid in a lipid nanoparticle host
ES2969956T3 (es) 2014-09-05 2024-05-23 Novartis Ag Lípidos y composiciones lipídicas para el suministro de agentes activos
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
US10888611B2 (en) 2015-02-19 2021-01-12 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
CN104844712B (zh) * 2015-04-03 2019-06-28 长春百克生物科技股份公司 肺炎链球菌蛋白抗原及其制备方法和应用
GB201509782D0 (en) * 2015-06-05 2015-07-22 Isis Innovation Methods and products for fusion protein synthesis
CA3008042A1 (en) * 2015-12-10 2017-06-15 National Research Council Of Canada Lipidated streptococcus pneumoniae antigen compositions, methods of preparation and use
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
EP3600400A4 (en) 2017-03-28 2021-01-13 The Children's Medical Center Corporation MULTIPLE ANTIGEN PRESENTATION SYSTEM (MAPS) BASED STAPHYLOCOCCUS AUREUS VACCINE, IMMUNOGEN COMPOSITION AND THEIR USES
GB201705750D0 (en) 2017-04-10 2017-05-24 Univ Oxford Innovation Ltd Peptide ligase and use therof
EP3634481A4 (en) 2017-06-10 2021-07-21 Inventprise, LLC. MULTIVALENT CONJUGATE VACCINES WITH BIVALENT OR MULTIVALENT CONJUGATE POLYSACCHARIDES THAT CONFIRM ENHANCED IMMUNOGENICITY AND AVIDITY
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
CN111065417B (zh) 2017-06-23 2024-04-19 美商艾芬尼维克斯公司 免疫原性组合物
TW202019470A (zh) 2018-09-12 2020-06-01 美商艾芬尼維克斯公司 多價肺炎球菌疫苗
KR102922338B1 (ko) 2018-09-12 2026-02-05 더 칠드런스 메디칼 센터 코포레이션 폐렴구균 융합 단백질 백신
EP4010014A1 (en) * 2019-08-05 2022-06-15 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2021059181A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2022035816A1 (en) 2020-08-10 2022-02-17 Inventprise, Llc Multivalent pneumococcal glycoconjugate vaccines containing emerging serotype 24f
EP4229208A4 (en) 2020-10-14 2024-10-30 George Mason Research Foundation, Inc. METHOD FOR THE PRODUCTION OF LIPID DNANOPARTICLES AND COMPOSITIONS THEREOF
WO2023021421A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Low-dose lyophilized rna vaccines and methods for preparing and using the same
US20240350410A1 (en) 2021-08-16 2024-10-24 Glaxosmithkline Biologicals Sa Freeze-drying of lipid nanoparticles (lnps) encapsulating rna and formulations thereof
WO2023039223A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
CN114507658B (zh) * 2022-04-02 2022-07-05 深圳瑞德林生物技术有限公司 酶共表达系统及其在合成唾液酸的应用
CA3256262A1 (en) * 2022-06-07 2025-03-18 Shanghai Alezyme Pharmaceuticals Ltd. Fusion proteins including truncated forms of immunoglobulin A (IGA) protease and their uses
WO2024006863A1 (en) 2022-06-30 2024-01-04 Precision NanoSystems ULC Lipid nanoparticle formulations for vaccines
CN116063548B (zh) * 2022-07-08 2025-06-10 中国人民解放军陆军军医大学 一种融合蛋白KP-Ag1及其用作肺炎克雷伯菌疫苗抗原的应用
GB202303019D0 (en) 2023-03-01 2023-04-12 Glaxosmithkline Biologicals Sa Method of lyophilisation
CN117736279A (zh) * 2023-04-21 2024-03-22 华中农业大学 胸膜肺炎放线杆菌的三个候选抗原及其应用
WO2024259508A1 (pt) 2023-06-22 2024-12-26 Instituto Butantan Antígeno multiepítopo, composição imunogênica compreendendo o referido antígeno, kit de diagnóstico do pneumococo, e usos do referido antígeno
AU2023457883A1 (en) 2023-06-28 2025-12-18 Global Life Sciences Solutions Canada Ulc Lipid nanoparticle formulations for cell therapy and related methods
GB202311382D0 (en) 2023-07-25 2023-09-06 Glaxosmithkline Biologicals Sa Lyophilised compostion
WO2026033498A1 (en) 2024-08-09 2026-02-12 Genvax Technologies, Inc. Methods of self-amplifying rna-lipid nanoparticle manufacture and compositions derived therefrom
CN118702827B (zh) * 2024-08-27 2025-03-07 南京澄实生物医药科技有限公司 一种预防肺炎链球菌感染的融合蛋白及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521058A (ja) * 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
WO2004092209A2 (en) * 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation

Family Cites Families (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
US4315919A (en) * 1980-10-06 1982-02-16 Edward Shanbrom Depyrogenation process
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
IL73534A (en) 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5916588A (en) 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US6090406A (en) 1984-04-12 2000-07-18 The Liposome Company, Inc. Potentiation of immune responses with liposomal adjuvants
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US5011828A (en) 1985-11-15 1991-04-30 Michael Goodman Immunostimulating guanine derivatives, compositions and methods
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5206152A (en) 1988-04-08 1993-04-27 Arch Development Corporation Cloning and expression of early growth regulatory protein genes
US5422120A (en) 1988-05-30 1995-06-06 Depotech Corporation Heterovesicular liposomes
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
NZ230423A (en) 1988-08-25 1993-08-26 Liposome Co Inc A dosage form comprising an antigen and a multilamellar liposome comprising dimyristolyphosphatidylcholine (dmpc) and cholesterol
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
US5238944A (en) 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US6716432B1 (en) 1988-12-16 2004-04-06 James Cleland Paton Pneumolysin mutants and pneumococcal vaccines made therefrom
DE68929323T2 (de) 1988-12-16 2002-04-18 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
EP0378881B1 (en) 1989-01-17 1993-06-09 ENIRICERCHE S.p.A. Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
WO1990007936A1 (en) 1989-01-23 1990-07-26 Chiron Corporation Recombinant therapies for infection and hyperproliferative disorders
ATE240401T1 (de) 1989-03-21 2003-05-15 Vical Inc Expression von exogenen polynukleotidsequenzen in wirbeltieren
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US4929624A (en) 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FI920131A0 (fi) 1989-07-14 1992-01-13 Praxis Biolog Inc Cytokin- och hormonbaerare foer konjugatvaccin.
EP0487587A1 (en) 1989-08-18 1992-06-03 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US4988815A (en) 1989-10-26 1991-01-29 Riker Laboratories, Inc. 3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
NZ237464A (en) 1990-03-21 1995-02-24 Depotech Corp Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5658731A (en) 1990-04-09 1997-08-19 Europaisches Laboratorium Fur Molekularbiologie 2'-O-alkylnucleotides as well as polymers which contain such nucleotides
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
US5149655A (en) 1990-06-21 1992-09-22 Agracetus, Inc. Apparatus for genetic transformation
GB2276169A (en) 1990-07-05 1994-09-21 Celltech Ltd Antibodies specific for carcinoembryonic antigen
DE69113564T2 (de) 1990-08-13 1996-05-30 American Cyanamid Co Faser-Hemagglutinin von Bordetella pertussis als Träger für konjugierten Impfstoff.
ES2144414T3 (es) 1990-12-20 2000-06-16 Arch Dev Corp The University O Control de la expresion de un gen por medio de una radiacion ionizante.
US5389640A (en) 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
EP0582581B1 (en) 1991-03-01 1999-05-06 Minnesota Mining And Manufacturing Company 1-SUBSTITUTED, 2-SUBSTITUTED 1H-IMIDAZO[4,5-c]QUINOLIN-4-AMINES
AU663725B2 (en) 1991-08-20 1995-10-19 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Adenovirus mediated transfer of genes to the gastrointestinal tract
US5936076A (en) 1991-08-29 1999-08-10 Kirin Beer Kabushiki Kaisha αgalactosylceramide derivatives
US5268376A (en) 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
WO1993010218A1 (en) 1991-11-14 1993-05-27 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Vectors including foreign genes and negative selective markers
GB9125623D0 (en) 1991-12-02 1992-01-29 Dynal As Cell modification
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
JPH07507689A (ja) 1992-06-08 1995-08-31 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 特定組織のターゲティング方法及び組成物
JPH09507741A (ja) 1992-06-10 1997-08-12 アメリカ合衆国 ヒト血清による不活性化に耐性のあるベクター粒子
NZ253137A (en) 1992-06-25 1996-08-27 Smithkline Beecham Biolog Vaccine comprising antigen and/or antigenic composition, qs21 (quillaja saponaria molina extract) and 3 de-o-acylated monophosphoryl lipid a.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
GB2269175A (en) 1992-07-31 1994-02-02 Imperial College Retroviral vectors
JPH08503855A (ja) 1992-12-03 1996-04-30 ジェンザイム・コーポレイション 嚢胞性線維症に対する遺伝子治療
US5395937A (en) 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
EP0689454B2 (en) 1993-03-23 2005-02-23 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
ATE227979T1 (de) 1993-04-22 2002-12-15 Skyepharma Inc Multivesikuläre liposomen mit verkapseltem cyclodextrin und pharmakologisch wirksamen verbindungen sowie verfahren zu deren verwendung
ES2249761T3 (es) 1993-06-24 2006-04-01 Advec Inc. Vectores de adenovirus para terapia genica.
US5352784A (en) 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
CZ288182B6 (en) 1993-07-15 2001-05-16 Minnesota Mining & Mfg Imidazo[4,5-c]pyridine-4-amines and pharmaceutical preparations based thereon
US6015686A (en) 1993-09-15 2000-01-18 Chiron Viagene, Inc. Eukaryotic layered vector initiation systems
EP0694070B1 (en) 1993-09-15 2002-04-10 Chiron Corporation Recombinant alphavirus vectors
SK283703B6 (sk) 1993-10-25 2003-12-02 Canji, Inc. Rekombinantný adenovírusový vektor a jeho použitie
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
DK0729351T3 (da) 1993-11-16 2000-10-16 Skyepharma Inc Vesikler med reguleret afgivelse af aktivstoffer
GB9326174D0 (en) 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
JP4303315B2 (ja) 1994-05-09 2009-07-29 オックスフォード バイオメディカ(ユーケー)リミテッド 非交差性レトロウイルスベクター
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
AU4594996A (en) 1994-11-30 1996-06-19 Chiron Viagene, Inc. Recombinant alphavirus vectors
US5482936A (en) 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
US5707829A (en) 1995-08-11 1998-01-13 Genetics Institute, Inc. DNA sequences and secreted proteins encoded thereby
US20020028215A1 (en) * 1999-08-09 2002-03-07 Jagath L. Kadurugamuwa Novel vaccines and pharmaceutical compositions using membrane vesicles of microorganisms, and methods for preparing same
DE69739286D1 (de) 1996-05-06 2009-04-16 Oxford Biomedica Ltd Rekombinationsunfähige retrovirale vektoren
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
GB9725084D0 (en) 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
WO1999040936A2 (en) 1998-02-12 1999-08-19 American Cyanamid Company Pneumococcal and meningococcal vaccines formulated with interleukin-12
US7018637B2 (en) 1998-02-23 2006-03-28 Aventis Pasteur, Inc Multi-oligosaccharide glycoconjugate bacterial meningitis vaccines
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
HUP0101619A3 (en) 1998-04-09 2003-11-28 Smithkline Beecham Biolog Adjuvant compositions
JP2002516251A (ja) 1998-04-23 2002-06-04 ユーエイビー リサーチ ファンデーション 肺炎球菌表面プロテインC(PspC)のエピトープ領域およびその菌株選択、ならびにそのための使用法
DK1075276T3 (da) 1998-05-07 2008-02-11 Corixa Corp Adjuvanssammensætning og fremgangsmåder til dens anvendelse
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20030134407A1 (en) * 1998-07-27 2003-07-17 Le Page Richard William Falla Nucleic acids and proteins from Streptococcus pneumoniae
EP2053126A1 (en) 1998-07-27 2009-04-29 Sanofi Pasteur Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US6110929A (en) 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
NZ509986A (en) 1998-08-19 2003-10-31 Baxter Healthcare S Immunogenic beta-propionamido-linked polysaccharide and oligosaccharide protein conjugates as vaccines
DE122007000087I1 (de) 1998-10-16 2008-03-27 Glaxosmithkline Biolog Sa Adjuvanzsysteme und impfstoffe
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
DK1140157T3 (da) 1998-12-21 2009-06-08 Medimmune Inc Streptococcus pneumoniae-proteiner og immunogene fragmenter til vacciner
US20030130212A1 (en) 1999-01-14 2003-07-10 Rossignol Daniel P. Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en) 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
DE60013773T2 (de) 1999-02-03 2005-11-10 Biosante Pharmaceuticals, Inc. Methoden zur Herstellung von therapeutischen Kalziumphosphat Partikeln
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
EP1165795A2 (en) 1999-03-26 2002-01-02 Provalis UK Limited Streptococcus pneumoniae antigens
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
ATE325620T1 (de) 1999-06-10 2006-06-15 Medimmune Inc Streptococcus pneumoniae proteine und impfstoffe
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
EP1075841A1 (en) 1999-08-13 2001-02-14 Erasmus Universiteit Rotterdam Pneumococcal vaccines
BR0014285A (pt) 1999-09-24 2002-05-21 Smithkline Beecham Biolog Adjuvantes compreendendo um éster ou éter de alquila de polioxietileno e pelo menos um tensoativo não-iÈnico
PL355163A1 (en) 1999-09-24 2004-04-05 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
TR200200797T2 (tr) 1999-09-25 2002-10-21 University Of Iowa Research Foundation İmmünostimülatör nükleik asitler
WO2001095935A1 (en) 2000-01-20 2001-12-20 Ottawa Health Research Institute Immunostimulatory nucleic acids for inducing a th2 immune response
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
JP2003530872A (ja) 2000-04-27 2003-10-21 メディミューン,インコーポレイテッド 免疫原肺炎連鎖球菌タンパク質とそのワクチン組成物
US20040091495A1 (en) 2000-07-20 2004-05-13 Lars Bjorck Protein
ES2334641T3 (es) 2000-09-01 2010-03-15 Novartis Vaccines And Diagnostics, Inc. Derivados aza heterociclicos y su uso terapeutico.
PL211125B1 (pl) 2000-09-11 2012-04-30 Novartis Vaccines & Diagnostic Pochodne chinolinonu jako inhibitory kinazy tyrozynowej, kompozycje je zawierające i ich zastosowanie
GB0022742D0 (en) 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
JP2004509970A (ja) 2000-09-26 2004-04-02 ハイブリドン・インコーポレイテッド 位置的化学変化による免疫刺激オリゴヌクレオチドアナログの免疫刺激活性の調節
EP1330473A2 (en) 2000-10-26 2003-07-30 Imperial College Innovations Limited Streptococcal genes
UA74852C2 (en) 2000-12-08 2006-02-15 3M Innovative Properties Co Urea-substituted imidazoquinoline ethers
US6664264B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6660747B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6660735B2 (en) 2000-12-08 2003-12-09 3M Innovative Properties Company Urea substituted imidazoquinoline ethers
US6677347B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Sulfonamido ether substituted imidazoquinolines
US6664265B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Amido ether substituted imidazoquinolines
US6667312B2 (en) 2000-12-08 2003-12-23 3M Innovative Properties Company Thioether substituted imidazoquinolines
US6677348B2 (en) 2000-12-08 2004-01-13 3M Innovative Properties Company Aryl ether substituted imidazoquinolines
US6664260B2 (en) 2000-12-08 2003-12-16 3M Innovative Properties Company Heterocyclic ether substituted imidazoquinolines
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0108079D0 (en) 2001-03-30 2001-05-23 Microbial Technics Ltd Protein
AU2002309706A1 (en) 2001-05-11 2002-11-25 Aventis Pasteur, Inc. Novel meningitis conjugate vaccine
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AU2002347404A1 (en) 2001-09-14 2003-04-01 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
WO2003035836A2 (en) 2001-10-24 2003-05-01 Hybridon Inc. Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
KR100718371B1 (ko) 2001-11-27 2007-05-14 애나디스 파마슈티칼스, 인코포레이티드 3-β-D-리보푸라노실티아졸로[4,5-d]피리디민누클레오시드 및 이의 용도
US7321033B2 (en) 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
US6677349B1 (en) 2001-12-21 2004-01-13 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US7071216B2 (en) 2002-03-29 2006-07-04 Chiron Corporation Substituted benz-azoles and methods of their use as inhibitors of Raf kinase
EP2275120A3 (en) 2002-04-02 2011-06-08 Ben-Gurion University Of The Negev Research And Development Authority Protein-based streptococcus pneumoniae vaccines
US6743920B2 (en) 2002-05-29 2004-06-01 3M Innovative Properties Company Process for imidazo[4,5-c]pyridin-4-amines
CA2487831A1 (en) 2002-06-11 2003-12-18 Glaxosmithkline Biologicals S.A. Immunogenic compositions
AU2003251518B2 (en) 2002-06-13 2009-07-02 New York University Synthetic C-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases
ATE477251T1 (de) 2002-08-23 2010-08-15 Novartis Vaccines & Diagnostic Pyrrolverbindungen als glykogen synthase kinase 3 inhibitoren
AU2003268353A1 (en) * 2002-08-30 2004-03-19 Tufts University Streptococcus pneumoniae antigens for diagnosis, treatment and prevention of active infection
JP2006506989A (ja) 2002-11-07 2006-03-02 シナジー アメリカ,インコーポレイテッド 肺炎球菌感染を治療または予防するための組成物および方法
AU2003300021A1 (en) 2002-12-27 2004-07-29 Chiron Corporation Thiosemicarbazones as anti-virals and immunopotentiators
US8193185B2 (en) 2003-01-21 2012-06-05 Novartis Vaccines And Diagnostics, Inc. Use of tryptanthrin compounds for immune potentiation
GB0301554D0 (en) 2003-01-23 2003-02-26 Molecularnature Ltd Immunostimulatory compositions
ES2423800T3 (es) 2003-03-28 2013-09-24 Novartis Vaccines And Diagnostics, Inc. Uso de compuestos orgánicos para la inmunopotenciación
RU2236257C1 (ru) 2003-09-15 2004-09-20 Косяков Константин Сергеевич Синтетический иммуноген для терапии и профилактики злоупотреблений наркотическими и психоактивными веществами
US7771726B2 (en) 2003-10-08 2010-08-10 New York University Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases
WO2005063283A1 (en) 2003-12-31 2005-07-14 Sungkyunkwan University Vaccine comprising recombinant clpp protein of streptococcus pneumoniae
AU2005235080A1 (en) 2004-03-31 2005-11-03 New York University Novel synthetic C-glycolipids, their synthesis and use to treat infections, cancer and autoimmune diseases
WO2005097181A1 (en) 2004-04-05 2005-10-20 Pfizer Products Inc. Microfluidized oil-in-water emulsions and vaccine compositions
GB0410220D0 (en) 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
WO2006084466A2 (en) * 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228369A1 (en) 2005-04-11 2006-10-12 Program For Appropriate Technology In Health Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en) 2005-04-15 2010-04-06 Merial Limited Vaccine formulations
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8703095B2 (en) 2005-07-07 2014-04-22 Sanofi Pasteur S.A. Immuno-adjuvant emulsion
CN103251940A (zh) 2005-12-22 2013-08-21 葛兰素史密丝克莱恩生物有限公司 疫苗
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
WO2007116322A2 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
AU2007229449A1 (en) * 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
PT2086582E (pt) 2006-10-12 2013-01-25 Glaxosmithkline Biolog Sa Vacina compreendendo uma emulsão adjuvante óleo em água
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US9493517B2 (en) * 2011-11-07 2016-11-15 Glaxosmithkline Biologicals Sa Conjugates comprising an antigen and a carrier molecule

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002521058A (ja) * 1998-07-27 2002-07-16 マイクロビアル テクニクス リミティッド 肺炎連鎖球菌由来の核酸及びタンパク質
WO2004092209A2 (en) * 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
WO2006128294A1 (en) * 2005-06-01 2006-12-07 Variation Biotechnologies Inc. Peptide-based influenza vaccine formulation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6013038931; Molecular Microbiology, 2006, Vol.59, No.3, p.961-974 *
JPN6013038933; Infect. Immun., 2000, Vol.68, No.6, p.3740-3743 *
JPN6013038936; J. Bacteriol., 2000, Vol.182, No.20, p.5919-5921 *
JPN6013038940; Microbes and Infection, 2005, Vol.7, p.1324-1337 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11779641B2 (en) 2011-04-29 2023-10-10 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
JP7389549B2 (ja) 2011-04-29 2023-11-30 セレクタ バイオサイエンシーズ インコーポレーテッド 抗体反応を低下させる寛容原性合成ナノキャリア
JP2021183612A (ja) * 2011-04-29 2021-12-02 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences, Inc. 細胞傷害性tリンパ球応答を低下させる寛容原性合成ナノキャリア
JP2021183616A (ja) * 2011-04-29 2021-12-02 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences, Inc. 抗体反応を低下させる寛容原性合成ナノキャリア
US11235057B2 (en) 2011-04-29 2022-02-01 Selecta Biosciences, Inc. Methods for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US11717569B2 (en) 2011-04-29 2023-08-08 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
JP2019065035A (ja) * 2011-04-29 2019-04-25 セレクタ バイオサイエンシーズ インコーポレーテッドSelecta Biosciences,Inc. 抗体反応を低下させる寛容原性合成ナノキャリア
JP2015501329A (ja) * 2011-11-07 2015-01-15 ノバルティス アーゲー spr0096抗原およびspr2021抗原を含むキャリア分子
US11298342B2 (en) 2013-05-03 2022-04-12 Selecta Biosciences, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both type I and type IV hypersensitivity
US12472167B2 (en) 2013-05-03 2025-11-18 Cartesian Therapeutics, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity
US12508249B2 (en) 2013-05-03 2025-12-30 Cartesian Therapeutics Inc. Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis
US11633422B2 (en) 2014-09-07 2023-04-25 Selecta Biosciences, Inc. Methods and compositions for attenuating anti-viral transfer vector immune responses
US11426451B2 (en) 2017-03-11 2022-08-30 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
US12194078B2 (en) 2017-03-11 2025-01-14 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Also Published As

Publication number Publication date
CN104001165B (zh) 2018-08-14
EP2197484A2 (en) 2010-06-23
DK2572726T3 (en) 2016-07-04
EA018137B1 (ru) 2013-05-30
EP2572726B1 (en) 2016-05-04
PL2572726T3 (pl) 2016-12-30
US20110243976A1 (en) 2011-10-06
CY1117689T1 (el) 2017-05-17
WO2009016515A3 (en) 2009-08-13
JP2014034578A (ja) 2014-02-24
AP2010005173A0 (en) 2010-02-28
BRPI0813892A2 (pt) 2017-05-09
HRP20160685T1 (hr) 2016-07-15
AU2008281438A1 (en) 2009-02-05
SI2572726T1 (sl) 2016-08-31
CO6260103A2 (es) 2011-03-22
GB0714963D0 (en) 2007-09-12
JP5838193B2 (ja) 2016-01-06
CA2695169A1 (en) 2009-02-05
EP2572726A1 (en) 2013-03-27
EA201070200A1 (ru) 2010-08-30
PT2572726T (pt) 2016-08-05
US20140348868A1 (en) 2014-11-27
WO2009016515A2 (en) 2009-02-05
ES2580957T3 (es) 2016-08-30
CN104001165A (zh) 2014-08-27
HUE029670T2 (en) 2017-03-28
CN101801409A (zh) 2010-08-11

Similar Documents

Publication Publication Date Title
JP5838193B2 (ja) 肺炎球菌抗原を含む組成物
CA2498847C (en) Group b streptococcus vaccine
JP6008741B2 (ja) 肺炎球菌RrgBクレイドの組み合わせ
JP5960121B2 (ja) Streptococcus agalactiaeの処置および予防のための免疫原性タンパク質および組成物
PL210198B1 (pl) Immunogenna kompozycja, jej zastosowanie i sposób wytwarzania oraz zawierająca ją szczepionka przeciwko Streptococcus pneumoniae
JP2008019262A (ja) Streptococcusagalactiaeのための免疫原性組成物
JP2012502073A (ja) H因子結合タンパク質免疫原
JP2008538183A (ja) B型インフルエンザ菌
JP2013520487A (ja) 免疫原性タンパク質および組成物
JP2017160238A (ja) ストレプトコッカス・ニューモニエ(Streptococcus pneumoniae)に対する融合抗原ワクチンおよび組成物
US8945589B2 (en) Immunogenic compositions for Streptococcus agalactiae
JP2018135388A (ja) シュードモナス抗原および抗原の組み合わせ
JP4771948B2 (ja) Streptococcusagalactiaeのための免疫原性組成物
JP2013510188A (ja) 黄色ブドウ球菌に由来する菌血症関連抗原

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110801

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110801

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20120719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20131224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140320

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140508